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Abstract
Background: The present study was designed to investigate whether teicoplanin minimum inhibitory
concentrations (MICs) of methicillin-resistant Staphylococcus aureus (MRSA) isolates play a role in the prognosis of
patient with teicoplanin-treated MRSA bloodstream infection (BSI).
Methods: Between 1 January 2006 and 31 December 2009, adult patients with teicoplanin-treated MRSA BSI in two
Taiwan medical centers were retrospectively enrolled. Their blood MRSA isolates were submitted for determination of
MICs to various antibiotics and multi-locus sequence types. All-cause mortalities on Days 14 and 30, as well as clinical
response at the end of teicoplanin therapy were treated as endpoints.
Results: Two hundred seventy adult patients were enrolled and 210 blood MRSA isolates were available. Independent
risk factors for un-favorable outcome at the end of teicoplanin therapy included septic shock (p < 0.0001) and an
elevated C-reactive protein level (p = 0.0064). The independent risk factors for all-cause Day 14 mortality (13.0%) included
the presence of auto-immune diseases (p = 0.0235), septic shock (p = 0.0253) and thrombocytopenia (p = 0.0018). The
independent risk factors for all-cause Day 30 mortality (26.3%) included age (p = 0.0102), septic shock (p < 0.0001) and
thrombocytopenia (p = 0.0059).
Conclusions: The current study didn’t find a significant role for teicoplanin MICs in the prognosis of adult patients with
teicoplanin-treated MRSA BSI.
Keywords: Teicoplanin, Methicillin-resistant Staphylococcus aureus, Bloodstream infection, Minimum inhibitory
concentration
Background
Methicillin-resistant Staphylococcus aureus (MRSA) is the
cause of several infection syndromes in community and
healthcare-associated settings [1-4]. Among these syn-
dromes, MRSA bloodstream infection (BSI) is of special
concern because of the association with significant mortal-
ity and morbidity [5-7].
Vancomycin has been the mainstay for treating MRSA
infections, including MRSA BSI, and continued to be
widely used in many countries. Although most clinical
MRSA isolates are susceptible to vancomycin, several stud-
ies have demonstrated that higher vancomycin minimum
inhibitory concentration (MIC) levels (≥ 1.5 mg/L) of the
causative MRSA isolates predict higher vancomycin treat-
ment failure rates, despite of being susceptible to vanco-
mycin [5,6,8,9]. A possible basis for this observation is that
an AUC/MIC ratio ≥ 400 is required to achieve clinical ef-
fectiveness when using vancomycin to treat S. aureus infec-
tions [10]; however, this target is difficult to achieve if the
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causative MRSA isolates have a vancomycin MIC > 1 mg/L
[10]. Another possible explanation is that a higher propor-
tion of heterogenous vancomycin-intermediate S. aureus
(hVISA) has been noted among MRSA with higher vanco-
mycin MICs [11].
Teicoplanin is another important glycopeptide which is
commonly used to treat β-lactam-resistant Gram-positive
pathogens, including MRSA, in European countries and
Taiwan, but is not licensed in the United States. Although
there has been no well-designed clinical study comparing
the clinical effectiveness between teicoplanin and vanco-
mycin in patients with MRSA infections, some in vitro
studies have demonstrated that clinical MRSA isolates are
more likely to tolerate teicoplanin than vancomycin [12,13].
Thus implies that the in vivo effect of tecioplanin against
MRSA might not be better than vancomycin. Clearly,
whether or not a higher teicoplanin MIC level (≥ 1.5 mg/L)
of the causative MRSA isolates predicts a higher teicoplanin
treatment failure rate requires confirmation. Only one
retrospective, single-center study concerning this issue is
available till our writing this article [14]. The present study
was therefore designed to determine the potential influence
of teicoplanin MICs on the teicoplanin treatment effect for
MRSA BSI.
Methods
Patients and data collection
Between 1 January 2006 and 31 December 2009, all adult
patients (age > 18 years) admitted to Taipei Veterans Gen-
eral Hospital (TVGH, a major tertiary teaching hospital
with 2,900 beds located in northern Taiwan) and National
Taiwan University Hospital (NTUH, a major tertiary
teaching hospital with 2,500 beds located in northern
Taiwan) with MRSA BSIs and no concomitant infections
caused by other organisms were potential study partici-
pants. The patients who received teicoplanin as initial
therapy for ≥ 3 days with a maintenance dosage of 6 mg/kg
every 24 hours adjusted by patients’ renal function were
retrospectively enrolled in the present study. If a patient
had two separate MRSA BSIs during the study period, the
first episode was considered in the current study. Patients
with one or more MRSA BSIs before the study period
documented in the medical records were excluded from
the present study. A MRSA BSI was defined as ≥ 1 culture
from a blood sample obtained at the time of fever (≥ 38°C)
yielding MRSA [15]. All the blood samples were taken as
standard patient care. The blood MRSA isolates pre-
served by the Departments of Laboratory Medicine at
TVGH and NTUH were obtained for subsequent mi-
crobiologic examinations, which were done in a central
laboratory.
A standardized case report form was designed to collect
patients’ demographic, clinical, and routine laboratory data,
including age, gender, primary focus of MRSA BSIs,
severity of infection (presence or absence of shock within
24 hours of onset) [16], underlying diseases, Charlson co-
morbidity index [17], and immune status [18] at the onset
of the MRSA BSIs. Laboratory data from serum or blood
collected 24 h before and/or after the onset of the MRSA
BSI included the levels of albumin, C-reactive protein
(CRP), creatinine, alanine aminotransferase, hemoglobin,
the leukocytes count, and the platelet count. The endpoints
were clinical response evaluated at the end of teicoplanin
therapy, and all-cause mortalities on Day 14 and Day 30.
Before using the collected data into statistic procedures,
the identification codes were fully encrypted to preserve
anonymity. This study was conducted according to the
Declaration of Helsinki and was approved by Institutional
Review Boards (IRBs) at TVGH (201107014IC) and
NTUH (NTUH-201011008RC). The IRBs waived the need
for informed consents (written and oral) from the partici-
pants because this was a retrospective observational study,
involved very minimal risk to the subjects, did not include
intention deception, and did not involve sensitive popula-
tions or topics. This waiver does not adversely affect the
rights and welfare of the subjects.
Definitions
Primary BSI was defined as a BSI without an obvious focus
or related to intravascular catheters. Hypoalbuminemia
was defined as a serum albumin level < 3.5 g/L. Impaired
renal function was defined as a serum creatinine level > 1.4
mg/dL. Abnormal liver function with clinical significance
was defined as a serum alanine aminotransferase level >
200 U/L (5 times the normal upper limit). Anemia was
defined as a hemoglobin level < 11 g/dL. An abnormal
leukocyte count was defined as > 12,000/μL or < 4,000/μL.
Thrombocytopenia was defined as a platelet count
< 150,000/μL. An adequate loading dose of teicoplanin
was defined as 6 mg/kg every 12 h for 3 doses. An ad-
equate maintenance dose of teicoplanin was defined as 6
mg/kg every 24 h, adjusted by renal function [19]. Clinical
response at the end of teicoplanin therapy was clarified as
cure, improvement or failure. Cure was defined as total
resolution of clinical symptoms and signs related to the
MRSA BSI. Improvement was defined as partial resolution
of clinical symptoms and signs (teicoplanin was
discontinued due to adverse effects or a switch to oral an-
tibiotics). Failure was defined as no improvement or wor-
sening of clinical symptoms and signs which results in the
necessity to change antibiotics, and/or mortality. In the
outcome analyses, both “cure” and “improvement” clinical
responses were grouped into “favorable” outcomes; “fail-
ure” was considered as an un-favorable outcome.
Microbiological studies
MICs of all available MRSA isolates to erythromycin,
clindamycin, gentamicin, tetracycline, trimethoprim/
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sulfamethoxazole, rifampin, ciprofloxacin, vancomycin,
teicoplanin, linezolid, and daptomycin were determined
using the broth micro-dilution method defined by the
Clinical and Laboratory Standards Institute (CLSI) [20].
S. aureus ATCC 29213 was used as an internal control
in each test. The breakpoints for susceptibility were de-
fined by the CLSI [21]. Susceptibility to teicoplanin was
also determined using the Etest. A high teicoplanin
MIC was defined as ≥ 2 mg/L by the broth micro-
dilution method or ≥ 1.5 mg/L by the Etest. Typing of
the multilocus sequence typing was performed as pre-
viously described [22].
Statistic analyses
Continuous variables are displayed as the mean ±
standard deviation (SD) and compared using the Stu-
dent’s t test, or displayed as the median and range and
compared with the Wilcoxon rank-sum test if the dis-
tributions were non-normal. Categorical variables were
compared with a chi-square or Fisher exact test if the
expected values were ≤ 10. Risk factors for all-cause
Day 14 and Day 30 mortalities, as well as un-favorable
outcome at the end of teicoplanin therapy were identi-
fied using logistic regression models. All variables were
initially evaluated by univariate analysis, and the variables
with a p value < 0.2 underwent multivariate analysis.
Variables with co-linearity were not simultaneously
considered in the final model of multivariate analysis.
A stepwise model comparison and Akaike’s information
criterion were used to determine the best model for
multivariate analysis. All statistics were performed using
SAS 9.2 (SAS Institute, Cary, NC, USA). All tests were
two-tailed and a p value < 0.05 was considered statistically
significant.
Results
During the study period, 655 and 717adult patients with
MRSA BSIs were admitted to TVGH and NTUH, respect-
ively. Sixty-nine and 201 patients at NTUH and TVGH re-
ceived teicoplanin as initial therapy for ≥ 3 days with an
adequate maintenance dosage for MRSA BSI and were en-
rolled in the present study finally, respectively. The age dis-
tribution of the study population was 71.3 ± 16.3 years.
The male-to-female ratio was 197:73. All of the patients
had one or more underlying diseases (Table 1). The
Charlson comorbidity index was 4.2 ± 2.3. One hundred
ten and 157 patients developed MRSA BSI while admitted
to the intensive care units, general wards, respectively, and
3 patients had community-acquired MRSA BSIs. One hun-
dred forty-five patients had primary BSIs (94 related to
intravascular catheters and 51 without an obvious focus).
The primary foci of the other 125 patients with MRSA
BSIs included the urinary tract (n = 12), respiratory tract
(n = 99), surgical site (n = 21), skin and soft tissue (n = 35),
Table 1 Demographic, clinical, laboratory, and
microbiologic data of the 270 adult patients with
teicoplanin-treated MRSA BSIs
Parameter No. (%)
Age (years) (mean ± SD) 71.3 ± 16.3
Gender (male/female) 197 (73.0%)/73 (27.0%)
Charlson comorbidity index (mean ± SD) 4.2 ± 2.3
Primary focus of bacteremia
Urinary tract 12 (3.8%)
Respiratory tract 99 (31.0%)
Surgical wound 21 (6.6%)
Skin 35 (11.0%)
Intra-abdominal 7 (2.2%)
Intravenous catheter 94 (29.5%)
No obvious focus 51 (16.0%)
Location of onset
ICU 110 (40.7%)
General ward 157 (58.1%)
Community 3 (1.1%)
Deep-seated abscess or osteomyelitis 65 (24.1%)
Infective endocarditis 32 (11.9%)
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and abdomen (n = 7). Sixty-five patients were complicated
with deep abscess formation or osteomyelitis, among
whom 35 patients received operations for drainage and/or
debridement. Thirty-two patients had concurrent infective
endocarditis. Thirty-seven patients developed septic shock
within 24 h of the onset of the MRSA BSIs.
The laboratory data at the onset of the BSIs are summa-
rized in Table 1. Abnormal white blood cell counts, anemia,
thrombocytopenia, hypoalbuminemia, clinical-significant ab-
normal liver function, and impaired renal function were
noted in 213, 158, 112, 25, 24, and 109 patients, respectively.
Teicoplanin was initiated within 48 h of the onset of
BSIs in 164 patients. An adequate teicoplanin loading
dose was established in 112 patients. The duration of
teicoplanin therapy was 19.0 ± 5.1days. Fifty-four patients
received combination therapy with rifampin (41 patients)
or gentamicin (13 patients). Forty-two patients developed
teicoplanin associated adverse events 11.3 ± 3.2 days after
usage of teicoplanin. These adverse events included dizzi-
ness in 11 patients, headache in nine, skin rash in eight,
fever in seven, leucopenia in seven, and thrombocytopenia
in three. All the adverse events were tolerable or resolved
after discontinual of teicoplanin (22 patients). At the end
of teicoplanin therapy, a favorable outcome was noted in
171 patients (a “cure” in 149 patients and “improvement”
in 22 patients), and un-favorable outcomes were noted in
99 patients (mortality in 61 patients, and not tolerated, ne-
cessitating to change antibiotics in 38 patients). The all-
cause Day 14 and Day 30 mortality rates were 13.0% (35
deaths) and 26.3% (71 deaths), respectively.
Two hundred ten non-duplicated MRSA isolates were
available for microbiologic analysis. Using the broth micro-
dilution method, the teicoplanin MICs were ≤ 1 mg/L in
161 isolates, 2 mg/L in 46 isolates, and 4 mg/L in 3 isolates.
Using the Etest method, the teicoplanin MICs were ≤ 1
mg/L in 87 isolates, 1.5 mg/L in 86 isolates, 2 mg/L in 32
isolates, and > 2 mg/L in 4 isolates. MLST showed that 120
isolates were ST239, 63 isolates were ST5, 16 isolates were
ST59, 4 isolates were ST89, 2 isolates were ST7, 2 isolates
were ST45, 2 isolates were ST573, and 1 isolate was ST444
(Table 2). A stratified analysis of teicoplanin MICs by se-
quence type (ST) revealed that a higher proportion of
MRSA isolates with a teicoplanin MIC ≥ 2 mg/L (by broth
dilution) was noted in ST5 MRSA isolates compared to
other sequence types (p = 0.0009, Table 2). The overall
susceptibilities to erythromycin, clindamycin, gentami-
cin, tetracycline, trimethoprim/sulfamethoxazole, rifam-
pin, ciprofloxacin, teicoplanin, vancomycin, linezolid,
and daptomycin were 2.4%, 7.1%, 6.2%, 31.9%, 41.4%,
79.1%, 8.1%, 100%, 100%, 100%, and 100%, respectively.
The drug susceptibilities stratified by sequence types are
listed in detail in Table 3.
Univariate analyses of risk factors for all-cause Day 14
and Day 30 mortalities, and unfavorable outcome at the
Table 1 Demographic, clinical, laboratory, and
microbiologic data of the 270 adult patients with







White blood cell count*
< 4,000/μL 36 (13.4%)
4,000 – 12,000/μL 106 (39.3%)










Abnormal liver function test with clinical significance*
Yes 24 (12.8%)
No 163 (87.2%)




Effective treatment within 48 hours*
Yes 164 (64.5%)
No 72 (35.5%)
Clinical response at the end of teicoplanin therapy
Favorable outcome 171 (63.3%)
Un-favorable outcome 99 (36.7%)
Day 14 all-cause death 35 (13.0%)
Day 30 all-cause death 71 (26.3%)
MIC of teicoplanin by dilution method*
≤1 mg/L 161 (76.7%)
2 mg/L 46 (21.9%)
4 mg/L 3 (1.4%)
MIC of teicoplanin by Etest*
≤1 mg/L 87 (41.4%)
1.5 mg/L 86 (41.0%)
2 mg/L 32 (15.2%)
> 2 mg/L 4 (1.9%)
*Missing data were noted in white blood cell count (1 patient), anemia (1),
thrombocytopenia (2), hypoalbuminemia (83), abnormal liver function with
clinical significance (42), abnormal renal function (6), and effective treatment
within 48 hours (34). Sequence typing and MIC determination were done in
only 210 MRSA isolates.
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end of teicoplanin therapy are summarized in Table 4. The
presence of auto-immune diseases, gastrointestinal tract
diseases, and clinical-significant abnormal liver function,
septic shock and thrombocytopenia at the time of presen-
tation were significantly associated with the all-cause Day
14 mortality. Age, the presence of abnormal renal function,
gastrointestinal tract diseases, septic shock, leukocytosis,
and thrombocytopenia at the time of presentation were
significantly associated with all-cause Day 30 mortality.
The presence of endocarditis, septic shock, and an elevated
CRP level at presentation were risk factors for un-favorable
outcome at the end of teicoplanin therapy. Combination
therapy with either rifampin or gentamicin was not a sig-
nificant factor associated with outcome. The development
of adverse events associated with teicoplanin was also not
a significant factor for treatment outcome (p = 0.4702 and
0.1129 for Day 14 and 30 all-cause mortality, respectively).
Based on multivariate analyses, the presence of auto-
immune diseases (odds ratio [OR], 3.44; 95% confidence
interval [CI], 1.18–10.00; p = 0.0235), septic shock (OR,
2.75; 95% CI, 1.13–6.68; p = 0.0253), and thrombocytopenia
at the time of presentation (OR, 3.58; CI, 1.61–7.96;
p = 0.0018) were risk factors predicting for all-cause Day 14
mortality. Age (OR, 1.03; 95% CI, 1.01–1.05; p = 0.0102),
septic shock (OR, 8.45; 95% CI, 3.83–18.65; p < 0.0001),
and thrombocytopenia at the time of presentation (OR,
2.33; 95% CI, 1.28–4.27; p = 0.0059) were risk factors
predicting for all-cause Day 30 mortality. Septic shock (OR,
12.00; 95% CI, 4.66 – 30.93; p < 0.0001) and an elevated
CRP level (OR, 1.05; 95% CI, 1.01–1.08; p = 0.0064) at the
time of presentation were risk factors predicting an un-
favorable outcome at the end of teicoplanin therapy. A high
teicoplanin MIC, either by the Etest or micro-broth dilution
method, of the causative MRSA isolate was not a significant
factor in the analyses for all-cause Day 14 (p = 0.80 and
0.60, respectively), Day 30 mortality (p= >0.99 and 0.17, re-
spectively), or an un-favorable outcome at the end of
teicoplanin therapy (p = 0.65 and 0.95, respectively).
For the 65 patients with abscess formation or osteomye-
litis, drainage or debridement is not a significant factors as-
sociated with Day 14 all-cause mortality and outcome
evaluated when discontinuing teicoplanin (p = 0.3526, and
0.3113). However, it is a protective factor independently
against Day 30 all-cause mortality (OR, 0.29; p = 0.0250).
Discussion
The present study demonstrated that all-cause Day 14
and Day 30 mortalities of adult patients with MRSA BSIs
treated by teicoplanin were 13.0% and 26.3%, respect-
ively, which is in agreement with prior studies.8–11 The
independent risk factors for all-cause Day 14 mortality
were presence of autoimmune diseases, septic shock,
and thrombocytopenia at the time of presentation. The
independent risk factors for all-cause Day 30 mortality
included age, septic shock, and thrombocytopenia at the
time of presentation. The independent risk factors for
un-favorable outcome at the end of teicoplanin therapy
included septic shock and an elevated CRP level at the
time of presentation. The teicoplanin MICs of causative
MRSA isolates did not significantly affect the all-cause
Day 14 and Day 30 mortalities, and un-favorable out-
comes at the end of teicoplanin therapy.
Teicoplanin is not approved for use in the USA, but is
widely used in Europe and Taiwan. Almost all previous
studies concerning the relationship between MIC values of
antibiotics used to treat MRSA infections and the treatment
outcomes have focused on vancomycin [5,6,8,9]. Only one
prior study conducted by Chang et al. discussed the rela-
tionship between teicoplanin MICs and clinical outcome of
patients with teicoplanin-treated MRSA bacteremia [14].
Further, Chang et al. suggested that a teicoplanin Etest MIC
cut-off value of 1.5 mg/L could be used as a predictor for
patients with teicoplanin-treated MRSA bacteremia in
terms of outcome at the end of teicoplanin therapy and
Table 2 Number and proportion of MRSA isolates with
teicoplanin MIC ≥ 2mg/L stratified by sequence types
Sequence types
(No. of total isolates)
No. of isolates
with teicoplanin
MIC ≥ 2 mg/L
Proportion of isolates
with teicoplanin
MIC ≥ 2 mg/L
5 (63) 27 42.9%
7 (2) 1 50.0%
45 (2) 0 0
59 (16) 1 6.3%
83 (4) 2 50.0%
239 (120) 18 15.0%
444 (1) 0 0
573 (2) 0 0
All (210) 49 23.6%
Table 3 Susceptibilities to various antibiotics of the 210 MRSA isolates with stratification by sequence types
Sequence type (No. of isolates) Ery. Clin. Gen. Tet. SXT Rif. Cip. Van. Tei. Lin. Dap.
ST5 (63) 0 0 0 87.3% 44.4% 58.7% 0 100% 100% 100% 100%
239 (120) 0.8% 6.7% 0 3.3% 40.0% 87.5% 0 100% 100% 100% 100%
Others (27) 14.8% 25.9% 48.1% 29.6% 40.7% 88.9% 63.0% 100% 100% 100% 100%
All (210) 2.4% 7.1% 6.2% 31.9% 41.4% 79.1% 8.1% 100% 100% 100% 100%
Abbreviation: Ery, erythromycin; Clin, clindamycin; Gen, gentamicin; Tet, tetracycline; SXT, trimethoprim/sulfamethoxazole; Rif, rifampin; Cip, ciprofloxacin; Van,
vancomycin; Tei, teicoplanin; Lin, linezolid; Dap, daptomycin.
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MRSA BSI-related mortality. Our study did not yield a
similar result. Different outcomes were used to evaluate the
potential role of teicoplanin MICs in these two studies. We
considered that whether or not patients’ deaths were di-
rectly related to MRSA BSIs was difficult to be clearly iden-
tified in a retrospective study, and therefore did not use
MRSA BSI-related mortality as one of the outcomes. Differ-
ences in the study populations might also have been
present. Only 101 patients from a single center were en-
rolled in the Chang et al. investigation [14]. In contrast,
there were 270 patients from 2 medical centers in the
present study. In the study conducted by Chang et al. [14],
whether or not patients with concomitant infections caused
by other pathogens were excluded from analysis was not
well addressed. All of the above imply that there were dif-
ferences in the study populations between these two stu-
dies. In addition, the all-cause Day 30 mortality was higher
in the Chang et al. study (35/101 v.s. 71/270, p = 0.11) [14].
Furthermore, as our study result, teicoplanin MIC is also
found to be not a significant factor predicting for all-cause
Table 4 Univariate analysis for risk factors for Day 14 and Day 30 mortalities, and unfavorable outcomes at end of
teicoplanin therapy
Variables Day 14 mortality Day 30 mortality Unfavorable outcome
OR p value OR p value OR p value
Age 1.01 0.3749 1.02 0.0138 1.02 0.0628
Sex (male to female) 0.67 0.3025 0.84 0.5748 1.06 0.8281
Charlson comorbidity index 1.10 0.7972 2.73 0.0974 1.04 0.4988
Onset in ICU 1.08 0.8307 2.71 0.1147 1.44 0.1587
Presence of metastatic foci 1.79 0.1337 1.48 0.2079 1.21 0.5225
Endocarditis 0.95 0.9338 2.17 0.8592 2.16 0.0430
Septic shock 3.08 0.0083 18.11 <0.0001 8.44 <0.0001
Primary bacteremia 0.90 0.7724 0.69 0.1781 0.73 0.2215
Cardiovascular diseases 1.04 0.9336 1.63 0.1452 1.54 0.1503
Respiratory diseases 0.71 0.4507 1.01 0.9698 0.92 0.7860
Neurologic diseases 0.60 0.2247 0.79 0.4384 0.77 0.3388
Gastrointestinal tract diseases 0.42 0.0415 0.48 0.0157 0.90 0.6976
Hepatobiliary diseases 0.62 0.3419 0.56 0.1292 0.65 0.1934
Genitourinary tract diseases 0.98 0.9619 1.52 0.1338 1.31 0.2996
Endocrinologic diseases 1.07 0.8595 1.43 0.2029 1.47 0.1290
Malignancies 0.78 0.5217 0.94 0.8247 1.01 0.9860
Autoimmune diseases 4.27 0.0044 1.98 0.1543 0.72 0.5218
Immunosuppression 1.45 0.3246 1.39 0.2654 1.19 0.5264
Abnormal white blood cell count
< 4,000/μL 1.26 0.6380 0.71 0.4259 0.79 0.5671
> 12,000/μL 0.49 0.0851 0.59 0.0798 0.89 0.6658
Anemia 1.22 0.5959 1.11 0.7155 1.38 0.2135
Thrombocytopenia 4.20 0.0003 2.43 0.0017 1.35 0.2357
Hypoalbuminemia 3.40 0.2427 1.12 0.8368 2.09 0.1375
Abnormal liver function with clinical significance 6.94 0.0214 3.04 0.1815 1.85 0.4593
Abnormal renal function 1.34 0.4481 2.06 0.0168 1.58 0.0856
C-reactive protein 1.00 0.9269 1.00 0.9232 1.04 0.0166
Without effective treatment within 48 hours 0.77 0.5428 1.20 0.5698 0.87 0.6310
Adequate loading dose 0.932 0.8488 0.76 0.3335 0.93 0.7845
Combination therapy 1.46 0.3666 0.76 0.4481 0.60 0.1322
Teicoplanin MIC by broth dilution 0.76 0.5983 1.65 0.1712 1.02 0.9451
Teicoplanin MIC by Etest 0.90 0.7976 1.00 0.9949 1.15 0.6451
Sequence types (ST5, ST239 compared to other types)
ST5 0.664 0.4758 0.61 0.2047 0.76 0.4346
ST239 1.54 0.2992 0.85 0.6109 1.02 0.9531
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Day 30 mortality in the Chang et al. study [14]. Therefore,
whether or not the teicoplanin MICs of the causative pa-
thogens play an important role in the outcome of adult pa-
tients with teicoplanin-treated MRSA BSIs needs further
study to validate.
The risk factors for mortality or un-favorable outcomes
in the study were similar to the risk factors disclosed by
prior ones [7,8]. Advanced age and the presence of auto-
immune diseases suggest the presence of poor host condi-
tions. Septic shock and thrombocytopenia at the time of
presentation as well as an elevated CRP level were all indi-
cators of the severity of MRSA BSIs. It was therefore rea-
sonable to conclude that these factors were associated
with a poorer outcome. In addition, whether undergoing
operations for drainage or debridement or not is a signifi-
cant factor associated with Day 30 all-cause mortality
among those 65 patients with abscess formation or osteo-
myelitis in our present study. This also echoed the prior
study results [23].
Our study also showed that MRSA isolates of ST5 had a
significantly increased proportion of high teicoplanin MICs
by broth dilution compared to those of other sequence
types among tested isolates (Table 2). Our previous study
also demonstrated that the MICs to antibiotics differed
among various strains of MRSA [24]. ST5 is the predomi-
nant MRSA strain in some Asian countries, such as Japan
and Korea [25]. It is not the predominant MRSA strain in
Taiwan currently; however, its prevalence has increased in
Taiwan during recent years [26]. If the proportion of ST5
MRSA strain among all MRSA continues to increase, and
ST5 MRSA becomes the predominant strain in Taiwan in
the future, a significant portion of clinical MRSA isolates
will have a high teicoplanin MIC at that time. In addition,
although the susceptibility breakpoint for teicoplanin to
S. aureus is ≤ 8 mg/L according to the CLSI, the suscepti-
bility breakpoint is ≤ 2 mg/L according to the European
Committee on Antimicrobial Susceptibility Testing
(EUCAST) [27]. If the susceptibility breakpoint provided
by the EUCAST is assumed, 3 (1.4%) isolates would be
considered teicoplanin non-susceptible. These three MRSA
isolates belonged to ST5, ST7, and ST239. In addition, a
previous study pointed out that the teicoplanin MICs de-
termined by broth micro-dilution could be underestimated
[28]. Therefore, the true non-susceptible rate to teicoplanin
in our present study might be higher. Because teicoplanin
is widely used in Taiwan, it is important to continue moni-
toring the molecular epidemiology of clinical MRSA iso-
lates and the teicoplanin MICs among MRSA isolates.
There were some limitations to our study. First, the
study was retrospective and therefore there was missing
data and MRSA isolates, thus compromising the analytic
results and causal inference. Second, some specialists
have suggested that the serum teicoplanin trough level
should be kept ≥ 10 mg/L to successfully treat MRSA
BSIs [29]; however, no commercialized method to deter-
mine the serum teicoplanin level was available during
our study period and we did not have data about the
serum teicoplanin trough level. Indeed, this has affected
our results.
Conclusions
In conclusion, our study did not show that the teicoplanin
MICs of causative MRSA isolates was a significant factor
affecting the all-cause Day 14 and Day 30 mortalities, and
un-favorable outcomes at the end of teicoplanin therapy
among patients with teicoplanin-treated MRSA BSIs. The
presence of auto-immune diseases, advanced age, and se-
verity of MRSA BSIs were the significant risk factors
predicting for outcomes. To conclude whether or not the
tecioplanin MICs will play a role in the outcome of pa-
tients with teicoplanin-treated MRSA BSIs, further studies
are indicated.
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